Compare Stocks: VYGR, RIGL, DBVT, and ACRS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$6.17 +3.7%	$5.77	$1.74 ▼ $6.60	$831.95M	0.79	1.59 million shs	1.75 million shs
DBVT DBV Technologies	$13.47 -1.7%	$14.58	$8.70 ▼ $26.18	$861.39M	-0.95	226,058 shs	43,079 shs
RIGL Rigel Pharmaceuticals	$48.67 +0.4%	$41.86	$24.95 ▼ $52.24	$900.49M	1.2	301,617 shs	104,916 shs
VYGR Voyager Therapeutics	$3.51 +3.8%	$3.32	$2.93 ▼ $5.55	$208.27M	1.32	436,979 shs	406,740 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+3.70%	+2.66%	-2.99%	+41.51%	+199.51%
DBVT DBV Technologies	-1.68%	-0.52%	-5.41%	-18.81%	+47.86%
RIGL Rigel Pharmaceuticals	+0.35%	+4.71%	+20.23%	+62.61%	+22.87%
VYGR Voyager Therapeutics	+3.85%	-0.85%	+13.23%	+5.41%	-4.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$6.17 +3.7%	$5.77	$1.74 ▼ $6.60	$831.95M	0.79	1.59 million shs	1.75 million shs
DBVT DBV Technologies	$13.47 -1.7%	$14.58	$8.70 ▼ $26.18	$861.39M	-0.95	226,058 shs	43,079 shs
RIGL Rigel Pharmaceuticals	$48.67 +0.4%	$41.86	$24.95 ▼ $52.24	$900.49M	1.2	301,617 shs	104,916 shs
VYGR Voyager Therapeutics	$3.51 +3.8%	$3.32	$2.93 ▼ $5.55	$208.27M	1.32	436,979 shs	406,740 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+3.70%	+2.66%	-2.99%	+41.51%	+199.51%
DBVT DBV Technologies	-1.68%	-0.52%	-5.41%	-18.81%	+47.86%
RIGL Rigel Pharmaceuticals	+0.35%	+4.71%	+20.23%	+62.61%	+22.87%
VYGR Voyager Therapeutics	+3.85%	-0.85%	+13.23%	+5.41%	-4.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$11.33	83.68% Upside
DBVT DBV Technologies	2.71	Moderate Buy	$48.50	260.06% Upside
RIGL Rigel Pharmaceuticals	2.43	Hold	$59.00	21.22% Upside
VYGR Voyager Therapeutics	2.75	Moderate Buy	$16.50	370.09% Upside

Current Analyst Ratings Breakdown

Latest VYGR, RIGL, DBVT, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
8/27/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/25/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/17/2026	RIGL Rigel Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$40.00 ➝ $49.00
8/17/2026	RIGL Rigel Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	RIGL Rigel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$57.00 ➝ $85.00
8/10/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/6/2026	RIGL Rigel Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/20/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$8.22M	104.97	N/A	N/A	$0.89 per share	6.93
DBVT DBV Technologies	N/A	N/A	N/A	N/A	$2.55 per share	N/A
RIGL Rigel Pharmaceuticals	$276.79M	3.25	$6.77 per share	7.19	$22.99 per share	2.12
VYGR Voyager Therapeutics	$34.46M	6.28	N/A	N/A	$2.51 per share	1.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	11/5/2026 (Estimated)
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
RIGL Rigel Pharmaceuticals	$367.02M	$16.32	2.98	11.27	N/A	116.30%	22.95%	17.19%	11/3/2026 (Estimated)
VYGR Voyager Therapeutics	-$119.72M	-$1.80	N/A	N/A	N/A	-312.63%	-57.92%	-45.00%	11/9/2026 (Estimated)

Latest VYGR, RIGL, DBVT, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
8/6/2026	Q2 2026	VYGR Voyager Therapeutics	-$0.4838	-$0.40	+$0.0838	-$0.40	$4.52 million	$3.17 million
8/4/2026	Q2 2026	RIGL Rigel Pharmaceuticals	$0.0877	$0.88	+$0.7923	$0.88	$55.28 million	$78.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
DBVT DBV Technologies	N/A	3.72	3.72
RIGL Rigel Pharmaceuticals	N/A	1.94	1.79
VYGR Voyager Therapeutics	N/A	7.51	7.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
DBVT DBV Technologies	71.74%
RIGL Rigel Pharmaceuticals	66.23%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
DBVT DBV Technologies	1.06%
RIGL Rigel Pharmaceuticals	10.47%
VYGR Voyager Therapeutics	12.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	139.82 million	133.11 million	Optionable
DBVT DBV Technologies	80	62.88 million	62.21 million	Optionable
RIGL Rigel Pharmaceuticals	160	18.50 million	16.57 million	Optionable
VYGR Voyager Therapeutics	100	61.62 million	53.79 million	Optionable

VYGR, RIGL, DBVT, and ACRS Headlines

Recent News About These Companies

BlackRock Inc. Takes $18.10 Million Position in Voyager Therapeutics, Inc. $VYGR

September 4 at 3:28 AM | marketbeat.com

Alumis (NASDAQ:ALMS) and Voyager Therapeutics (NASDAQ:VYGR) Critical Analysis

September 4 at 2:15 AM | americanbankingnews.com

Voyager to Present at Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

Voyager Therapeutics (NASDAQ:VYGR) Stock Price Crosses Above Fifty Day Moving Average - Here's What Happened

August 29, 2026 | marketbeat.com

TD Cowen Remains a Buy on Voyager Therapeutics (VYGR)

August 24, 2026 | theglobeandmail.com

Voyager Therapeutics (NASDAQ:VYGR) Stock Price Passes Above 50-Day Moving Average - What's Next?

August 21, 2026 | marketbeat.com

HC Wainwright Brokers Raise Earnings Estimates for VYGR

August 12, 2026 | marketbeat.com

Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright

August 10, 2026 | marketbeat.com

Voyager Therapeutics (NASDAQ:VYGR) Issues Quarterly Earnings Results

August 6, 2026 | marketbeat.com

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Voyager Reports Second Quarter 2026 Financial and Operating Results

August 6, 2026 | finance.yahoo.com

Voyager Therapeutics: Q2 Earnings Snapshot

August 6, 2026 | khou.comK

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst

August 4, 2026 | theglobeandmail.com

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

July 13, 2026 | markets.businessinsider.com

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026

July 13, 2026 | globenewswire.com

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money

July 2, 2026 | aol.comA

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money

July 2, 2026 | 247wallst.com

Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside

June 30, 2026 | finance.yahoo.com

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

June 29, 2026 | markets.businessinsider.com

Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

June 29, 2026 | globenewswire.com

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

June 11, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR, RIGL, DBVT, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$6.17 +0.22 (+3.70%)

As of 09/4/2026 04:00 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

DBV Technologies NASDAQ:DBVT

$13.47 -0.23 (-1.68%)

As of 09/4/2026 04:00 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Rigel Pharmaceuticals NASDAQ:RIGL

$48.67 +0.17 (+0.35%)

As of 09/4/2026 04:00 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Voyager Therapeutics NASDAQ:VYGR

$3.51 +0.13 (+3.85%)

As of 09/4/2026 04:00 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VYGR, RIGL, DBVT, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VYGR, RIGL, DBVT, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VYGR, RIGL, DBVT, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR, RIGL, DBVT, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

DBV Technologies NASDAQ:DBVT

Rigel Pharmaceuticals NASDAQ:RIGL

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VYGR, RIGL, DBVT, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VYGR, RIGL, DBVT, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VYGR, RIGL, DBVT, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR, RIGL, DBVT, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

DBV Technologies NASDAQ:DBVT

Rigel Pharmaceuticals NASDAQ:RIGL

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools